BioCryst Pharmaceuticals | 流动负债



金融业
股票价格
USD
资产
USD 446.42M
现金及等价物
USD 84.08M
销售成本
USD 12.27M
流动资产
USD 355.68M
流动负债
USD 190.24M
债务
USD 828.6M
股息收益率
0
EBIT
USD -4.51M
EBITDA
USD -20.3M
员工
536
EPS每股收益
USD -0.13
股本和储备
USD -387.89M
销售毛利
USD -88.88M
债务利息支出
USD 24.45M
利息收入
USD -0.13
贷款资金
USD 194.37M
市值
USD 1.8B
净收入
USD -88.88M
营业费用
USD -387.89M
营业利润
USD -2.54M
普通股股本
USD 1.9M
PE价格收益
1.08K
税前利润
USD -86.95M
销售收入
USD -86.95M
销售和管理费用
USD 80.47M
股票
USD 5.23M
贸易债权人
USD 5.57M
应收帐款人
USD 79.07M


流动负债 更改 日
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
BioCryst Pharmaceuticals USD 190.24M 13.08M 2025-09
Chugai Pharma JPY 411.08B 143.65B 2025-12
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
DBV Technologies USD 49.48M 60K 2025-09
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Glaxosmithkline GBP 28.68B 8.3B 2025-09
Incyte USD 1.52B 176.44M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novavax USD 429.87M 40.73M 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12


BioCryst Pharmaceuticals 流动负债 - 当前值，历史数据，预测，统计，图表和经济日历 - Mar 2026.